BARDA loses leader in middle of race to create COVID-19 vaccine

Rick Bright (PHE.gov)

The U.S. agency leading efforts to develop a vaccine against COVID-19 has lost its leader. Rick Bright, a vaccine specialist, is moving to a new role in the National Institutes of Health (NIH) at a time when his former employer is scrambling to help biopharma make a COVID-19 prophylactic available.

In recent weeks, the Biomedical Advanced Research and Development Authority (BARDA), the group Bright led, has played a key role in adding financial muscle to COVID-19 vaccine programs, inking a $483 million agreement with Moderna and teaming up with Johnson & Johnson to funnel $1 billion into its candidate.

As director of BARDA, Bright oversaw the agreements. Bright looked to have credentials tailor-made for the situation, with stints leading BARDA’s flu pandemic preparations and working on vaccine R&D at Novavax on his résumé. Yet, as Stat first reported, Bright has now left BARDA.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

Bright has moved over to a role at the NIH that will see him to contribute to efforts to develop tests for COVID-19 that can be done at the point of care. A spokesperson for the Department of Health and Human Services said Bright will apply his “experience and expertise in facilitating powerful public-private partnerships” to “a bold plan to accelerate the development and deployment of novel point-of-care testing platforms.” 

RELATED: Biopharma's no-holds-barred fight to find a COVID-19 vaccine: The full list

The new work overlaps with some of the projects Bright was involved in while at BARDA, such as pandemic preparations that modeled the impact of using at-home diagnostics and wearables to enable early virus detection.

BARDA’s work suggested such technologies could flatten the curve, buying the U.S. time to develop a vaccine capable of stopping a pandemic. The U.S. and the rest of the world are now living in a version of that model, but responsibility for enacting BARDA’s plan will fall on someone else.

SPECIAL REPORT: The top 20 pharma companies by 2019 revenue

In the interim, Gary Disbrow, who deputized for Bright at BARDA, is stepping up to the director post. The temporary promotion of Disbrow, who has worked at BARDA since early 2007, could reduce the disruption caused by the change of leader during the middle of a pandemic.

Disbrow also has a background that is a good fit for the current crisis. Before joining BARDA, Disbrow worked on viruslike particle vaccines at Georgetown Medical Center, including on research that led to the development and approval of Merck’s Gardasil. Since joining BARDA, Disbrow has played a role in initiatives such as development of a smallpox vaccine and creation of medical countermeasures

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.